| Primary |
| Bipolar I Disorder |
42.9% |
| Maternal Exposure Timing Unspecified |
21.4% |
| Squamous Cell Carcinoma |
21.4% |
| Bipolar Disorder |
7.1% |
| Product Used For Unknown Indication |
7.1% |
|
| Heart Disease Congenital |
33.3% |
| Renal Failure Acute |
33.3% |
| Withdrawal Syndrome |
33.3% |
|
| Secondary |
| Product Used For Unknown Indication |
16.7% |
| Bipolar I Disorder |
14.7% |
| Drug Use For Unknown Indication |
13.4% |
| Bipolar Disorder |
13.2% |
| Schizophrenia |
6.4% |
| Insomnia |
4.7% |
| Psychotic Disorder |
4.3% |
| Agitation |
3.5% |
| Mania |
3.1% |
| Hypothyroidism |
2.9% |
| Parkinson's Disease |
2.9% |
| Depression |
2.1% |
| Sleep Disorder |
2.1% |
| Drug Exposure During Pregnancy |
1.7% |
| Epilepsy |
1.7% |
| Schizoaffective Disorder |
1.7% |
| Hypertension |
1.6% |
| Anxiety |
1.2% |
| Diabetes Mellitus |
1.2% |
| Breast Cancer |
1.0% |
|
| Tremor |
8.3% |
| Cerebellar Syndrome |
7.1% |
| Transaminases Increased |
7.1% |
| Treatment Noncompliance |
7.1% |
| Sinoatrial Block |
6.0% |
| Suicide Attempt |
6.0% |
| Therapeutic Agent Toxicity |
6.0% |
| Diarrhoea |
4.8% |
| Oedema |
4.8% |
| Overdose |
4.8% |
| Psychomotor Retardation |
4.8% |
| Renal Failure |
4.8% |
| Renal Failure Acute |
4.8% |
| Status Epilepticus |
4.8% |
| Hypercalcaemia |
3.6% |
| Muscle Rigidity |
3.6% |
| Toxic Epidermal Necrolysis |
3.6% |
| Ventricular Fibrillation |
3.6% |
| Drug Dispensing Error |
2.4% |
| Electrolyte Imbalance |
2.4% |
|
| Concomitant |
| Drug Use For Unknown Indication |
28.6% |
| Bipolar Disorder |
16.1% |
| Product Used For Unknown Indication |
10.4% |
| Depression |
9.2% |
| Insomnia |
7.3% |
| Bipolar I Disorder |
4.4% |
| Anxiety |
3.5% |
| Dysthymic Disorder |
2.3% |
| Breast Cancer |
2.1% |
| Psychotic Disorder |
2.1% |
| Schizophrenia |
1.9% |
| Hypomania |
1.7% |
| Ill-defined Disorder |
1.7% |
| Schizoaffective Disorder |
1.7% |
| Depressive Symptom |
1.5% |
| Mental Disorder |
1.5% |
| Thyroid Disorder |
1.3% |
| Diffuse Large B-cell Lymphoma |
1.0% |
| Hypercholesterolaemia |
1.0% |
| Affective Disorder |
0.8% |
|
| Vomiting |
13.0% |
| Urinary Tract Infection |
8.7% |
| Weight Decreased |
8.7% |
| Drug Interaction |
5.8% |
| Hepatitis Cholestatic |
5.8% |
| Major Depression |
5.8% |
| Vertigo |
5.8% |
| Platelet Count Increased |
4.3% |
| Polydipsia Psychogenic |
4.3% |
| Somnolence |
4.3% |
| Subileus |
4.3% |
| Transaminases Increased |
4.3% |
| Type 2 Diabetes Mellitus |
4.3% |
| Coma |
2.9% |
| Confusional State |
2.9% |
| Congestive Cardiomyopathy |
2.9% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
2.9% |
| Encephalitis |
2.9% |
| Hypomania |
2.9% |
| Intestinal Obstruction |
2.9% |
|
| Interacting |
| Product Used For Unknown Indication |
46.0% |
| Drug Use For Unknown Indication |
17.5% |
| Bipolar I Disorder |
15.9% |
| Depression |
6.3% |
| Gastrointestinal Disorder |
3.2% |
| Back Pain |
1.6% |
| Bipolar Disorder |
1.6% |
| Confusional State |
1.6% |
| Haemochromatosis |
1.6% |
| Hepatitis C |
1.6% |
| Major Depression |
1.6% |
| Obesity |
1.6% |
|
| Ventricular Dysfunction |
20.0% |
| Drug Interaction |
10.0% |
| Somnolence |
10.0% |
| Tremor |
10.0% |
| Vomiting |
10.0% |
| Drug Level Increased |
5.0% |
| Hyperthyroidism |
5.0% |
| Myalgia |
5.0% |
| Nervous System Disorder |
5.0% |
| Renal Failure Acute |
5.0% |
| Sinus Bradycardia |
5.0% |
| Suicidal Ideation |
5.0% |
| Tension |
5.0% |
|
